作者: Patrick S. Parfrey
DOI: 10.1111/J.1525-139X.2011.00949.X
关键词: Immunology 、 Kidney disease 、 Medicine 、 Hemoglobin 、 Anemia 、 Erythropoietin 、 Maintenance therapy
摘要: Hyporesponsiveness to erythropoietin stimulating agents occurs frequently, and may be observed at initiation of treatment or during maintenance therapy. An inverse relationship between hyporesponsiveness incident cardiovascular events has been reported. It is related least in part co-morbidity its occurrence requires a search for the cause. Treatment anemia hyporesponsive patients should individualized, with consideration given indication ESA therapy, target hemoglobin maximal dose limitations.